Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis

Journal of Paediatrics and Child Health

Volumn 36, Issue 5, 2000, Pages 422-427

  Numa, A ^a  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

Cost benefit; Mortality; Outcome; Prophylaxis; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RIBAVIRIN; SALBUTAMOL;

ARTICLE; ARTIFICIAL VENTILATION; BRONCHIOLITIS; CHILD; CONSERVATIVE TREATMENT; COST BENEFIT ANALYSIS; DISEASE CONTROL; FEMALE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFANT; INTENSIVE CARE; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETROSPECTIVE STUDY; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; AUSTRALIA; COST-BENEFIT ANALYSIS; HOSPITALIZATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; LENGTH OF STAY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 0033808325     PISSN: 10344810     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1754.2000.00303.x     Document Type: Article

References (47)

1. Respiratory syncytial virus puzzle: Clinical features, pathophysiology, treatment and prevention
2. Epidemiology of acute lower respiratory disease in children
3. Intensive care course and outcome of patients infected with respiratory syncytial virus
4. Management of respiratory failure in infants with acute viral bronchiolitis
5. RSV infection in high risk hospitalized children
6. Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure
7. Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection
8. Effect of bronchodilators on respiratory resistance in infants and young children with bronchiolitis and wheezing bronchitis
9. Nebulised therapy in acute severe bronchiolitis in infancy
10. Paradoxical deterioration in lung function after nebulised salbutamol in wheezy infants
11. Effect of salbutamol on respiratory mechanics in bronchiolitis
12. Paradoxical response to nebulised salbutamol in wheezy infants, assessed by partial expiratory flow-volume curves
13. Effect of salbutamol on oxygen saturation in bronchiolitis
14. Bronchodilators for treatment of mild bronchiolitis: A factorial randomised trial
15. Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis
16. Albuterol responsiveness in infants with respiratory failure caused by respiratory syncytial virus infection
17. Dexamethasone in bronchiolitis: A randomised controlled trial
18. Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: A randomized controlled trial
19. Early nebulized budesonide in the treatment of bronchiolitis and the prevention of postbronchiolitic wheezing
20. Efficacy of adding nebulized ipratropium bromide to nebulized albuterol therapy in acute bronchiolitis
21. Efficacy of bronchodilators in the treatment of bronchiolitis
22. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
23. Respiratory syncytial virus vaccines
24. Prophylactic administration of respiratory syncytial virus immune globulin to high risk infants and young children
25. Development of a humanized monoclonal antibody (MEDI-493) with potent in-vitro and in-vivo activity against respiratory syncytial virus
26. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis
27. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
28. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV
29. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children
30. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections
31. Respiratory syncytial virus immmune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease
32. Respiratory syncytial viral infection in infants with congenital heart disease
33. Respiratory problems 2 years after acute bronchiolitis in infancy
34. Acute bronchiolitis in infancy. The relationship to later recurrent obstructive airways disease
35. Asthma and wheezing in the first six years of life
36. Role of antibody and use of respiratory syncytial virus (RSV) immune globulin to prevent severe RSV disease in high-risk children
37. IMpact-RSV study group report
38. RSV-IGIV therapy: A cost/benefit analysis
39. Cost-effectiveness of RespiGam at a university teaching hospital
40. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birthweight infants
41. A number needed to treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization
42. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants
43. Questions about Palivizumab (Synagis)
44. Comments on Palivizumab (Synagis)
45. IMpact-RSV study group report